Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CD19/BCMA-Targeted CAR-T Cell Injection in Patients With Autoantibody-Mediated Autoimmune Diseases

NCT07596680 is registered in ClinicalTrials.gov with Nanjing Bioheng Biotech Co., Ltd. as lead sponsor.

NCT NCT07596680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07596680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CD19/BCMA-Targeted CAR-T Cell Injection in Patients With Autoantibody-Mediated Autoimmune Diseases
Lead sponsor
Nanjing Bioheng Biotech Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
April 30, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated vasculitis, idiopathic inflammatory myopathies, sjögren syndrome, sle - systemic lupus erythematosus, systemic sclerosis